Mannkind (MNKD) Non-Current Deferred Tax Liability (2018)
Mannkind (MNKD) reported Non-Current Deferred Tax Liability of $400000.0 for Q4 2018.
Mannkind (MNKD) has 1 years of Non-Current Deferred Tax Liability data on file, last reported at $400000.0 in Q4 2018.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $400000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $400000.0 (changed N/A YoY) and the FY2018 annual result came in at $400000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was little changed at $400000.0 in Q4 2018 per MNKD's latest filing.
- Across five years, Non-Current Deferred Tax Liability topped out at $400000.0 in Q4 2018 and bottomed at $400000.0 in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 400,000.00 |
| Dec 31, 2018 | 400,000.00 |